Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference
01. Juni 2022 16:01 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
16. Mai 2022 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
10. Mai 2022 07:00 ET
|
Aclaris Therapeutics, Inc.
Clinical Sites Activated for Phase 2b Trial of ATI-1777April Capital Raise Extends Cash Runway Through End of 2025 WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:...
Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium
03. Mai 2022 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
24. Februar 2022 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference
02. Februar 2022 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Expands Leadership Team
01. Februar 2022 16:01 ET
|
Aclaris Therapeutics, Inc.
Appoints James Loerop as Chief Business Officer WAYNE, Pa., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on...
Aclaris Therapeutics Provides R&D Update
11. Januar 2022 16:01 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
27. Dezember 2021 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine
03. Dezember 2021 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...